Editas Medicine/$EDIT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Editas Medicine
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- Ticker
- $EDIT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 87
- Headquarters
- Cambridge, United States
- Website
- www.editasmedicine.com
Editas Medicine Metrics
BasicAdvanced
$395M
-
-$0.73
2.09
-
Price and volume
Market cap
$395M
Beta
2.09
52-week high
$3.94
52-week low
$1.66
Average daily volume
2.3M
Financial strength
Current ratio
3.187
Quick ratio
3.133
Long term debt to equity
0.085
Total debt to equity
0.147
Interest coverage (TTM)
-20.52%
Profitability
EBITDA (TTM)
-81.035
Gross margin (TTM)
-80.74%
Net profit margin (TTM)
-157.32%
Operating margin (TTM)
-177.56%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-23.29%
Return on equity (TTM)
-118.82%
Valuation
Price to revenue (TTM)
5.533
Price to book
3.75
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
-2.157
Free cash flow yield (TTM)
-46.35%
Free cash flow per share (TTM)
-1.191
Growth
Revenue change (TTM)
20.83%
Earnings per share change (TTM)
-74.35%
3-year revenue growth (CAGR)
34.51%
10-year revenue growth (CAGR)
23.59%
3-year earnings per share growth (CAGR)
-37.29%
10-year earnings per share growth (CAGR)
-14.71%
What the Analysts think about Editas Medicine
Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.
Analyst projections of the future price of Editas Medicine stock.
Bulls say / Bears say
Editas has clearance to start the first-in-human Phase 1/2 trial of EDIT-401 in Australia, moving its lead programme from preclinical work into clinical testing. Initial safety data are expected in the first quarter of 2027. (U.S. Securities and Exchange Commission)
In non-human primates, a single dose of EDIT-401 produced mean reductions of about 90% or more in LDL cholesterol, Lp(a) and ApoB; LDL reduction was maintained for 10 months in an ongoing study. If these effects translate to people, the treatment could offer broad and durable lipid lowering. (U.S. Securities and Exchange Commission)
Editas reported $211.6 million in cash and equivalents at the end of June and expects its funds to cover operating and capital needs into the second half of 2028. This gives it time to advance EDIT-401 through planned clinical milestones before needing to raise more capital. (Editas Medicine)
Editas discontinued development of reni-cel, a major clinical programme, after deciding not to pursue it further. That history shows the risk that development programmes may be abandoned before they produce a commercial medicine. (U.S. Securities and Exchange Commission)
EDIT-401’s striking results so far come from non-human primates, not patients, so its safety and cholesterol-lowering effect in people remain unknown. The first safety update is expected in early 2027, with dose-finding results later that year. (U.S. Securities and Exchange Commission)
The May financing involved 55.6 million new shares and warrants to buy up to a further 55.6 million shares. If the warrants are exercised, existing shareholders’ ownership could be diluted further. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Editas Medicine Financial Performance
Revenues and expenses
Editas Medicine Earnings Performance
Company profitability
Upcoming events
No upcoming events
Editas Medicine News
AllArticlesVideos
Funds containing Editas Medicine
Fund name | Fund size | $EDIT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.03% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.02% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.02% |
iShares Ageing Population$AGED | $953M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.